View Item 

Show simple item record

Number of Unfavorable Intermediate‐Risk Factors Predicts Pathologic Upstaging and Prostate Cancer‐Specific Mortality Following Radical Prostatectomy: Results From the SEARCH Database
dc.contributor.authorZumsteg, Zachary S.
dc.contributor.authorChen, Zinan
dc.contributor.authorHoward, Lauren E.
dc.contributor.authorAmling, Christopher L.
dc.contributor.authorAronson, William J.
dc.contributor.authorCooperberg, Matthew R.
dc.contributor.authorKane, Christopher J.
dc.contributor.authorTerris, Martha K.
dc.contributor.authorSpratt, Daniel E.
dc.contributor.authorSandler, Howard M.
dc.contributor.authorFreedland, Stephen J.
dc.date.accessioned2017-01-10T19:08:12Z
dc.date.available2018-04-02T18:03:23Zen
dc.date.issued2017-02
dc.identifier.citationZumsteg, Zachary S.; Chen, Zinan; Howard, Lauren E.; Amling, Christopher L.; Aronson, William J.; Cooperberg, Matthew R.; Kane, Christopher J.; Terris, Martha K.; Spratt, Daniel E.; Sandler, Howard M.; Freedland, Stephen J. (2017). "Number of Unfavorable Intermediate‐Risk Factors Predicts Pathologic Upstaging and Prostate Cancer‐Specific Mortality Following Radical Prostatectomy: Results From the SEARCH Database." The Prostate 77(2): 154-163.
dc.identifier.issn0270-4137
dc.identifier.issn1097-0045
dc.identifier.urihttps://hdl.handle.net/2027.42/135480
dc.publisherWiley Periodicals, Inc.
dc.subject.otherunfavorable intermediate risk
dc.subject.otherprostate cancer
dc.subject.otherintermediate risk
dc.subject.otherfavorable intermediate risk
dc.titleNumber of Unfavorable Intermediate‐Risk Factors Predicts Pathologic Upstaging and Prostate Cancer‐Specific Mortality Following Radical Prostatectomy: Results From the SEARCH Database
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelInternal Medicine and Specialties
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/135480/1/pros23255.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/135480/2/pros23255_am.pdf
dc.identifier.doi10.1002/pros.23255
dc.identifier.sourceThe Prostate
dc.identifier.citedreferenceStephenson AJ, Eggener SE, Hernandez AV, Klein EA, Kattan MW, Wood DP Jr, Rabah DM, Eastham JA, Scardino PT. Do margins matter? The influence of positive surgical margins on prostate cancer‐specific mortality. Eur Urol 2014; 65: 675 – 680.
dc.identifier.citedreferenceSundi D, Wang VM, Pierorazio PM, Han M, Bivalacqua TJ, Ball MW, Antonarakis ES, Partin AW, Schaeffer EM, Ross AE. Very‐high‐risk localized prostate cancer: Definition and outcomes. Prostate Cancer Prostatic Dis 2014; 17: 57 – 63.
dc.identifier.citedreferenceBeltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G, Huang J, True L, Gleave ME, Soule H, Logothetis C, Rubin MA. Aggressive variants of castration‐resistant prostate cancer. Clin Cancer Res 2014; 20: 2846 – 2850.
dc.identifier.citedreferenceMohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D’Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kane CJ, Kawachi MH, Kuettel M, Kuzel TM, Lee RJ, Malcolm AW, Miller D, Plimack ER, Pow‐Sang JM, Raben D, Richey S, Roach M 3rd, Rohren E, Rosenfeld S, Schaeffer E, Small EJ, Sonpavde G, Srinivas S, Stein C, Strope SA, Tward J, Shead DA, Ho M; National Comprehensive Cancer Network. Prostate cancer, version 2. J Natl Compr Canc Netw 2014; 718: 2014.
dc.identifier.citedreferenceZumsteg ZS, Spratt DE, Pei I, Zhang Z, Yamada Y, Kollmeier M, Zelefsky MJ. A new risk classification system for therapeutic decision making with intermediate‐risk prostate cancer patients undergoing dose‐escalated external‐beam radiation therapy. Eur Urol 2013; 64: 895 – 902.
dc.identifier.citedreferenceCancer Genome Atlas Research N. The molecular taxonomy of primary prostate cancer. Cell 2015; 163: 1011 – 1025.
dc.identifier.citedreferenceZumsteg ZS, Zelefsky MJ. Short‐term androgen deprivation therapy for patients with intermediate‐risk prostate cancer undergoing dose‐escalated radiotherapy: The standard of care ? Lancet Oncol 2012; 13: e259 – e269.
dc.identifier.citedreferenceKeane FK, Chen MH, Zhang D, Loffredo MJ, Kantoff PW, Renshaw AA, D’Amico AV. The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate‐risk disease. Cancer 2014; 120: 1787 – 1793.
dc.identifier.citedreferenceKeane FK, Chen MH, Zhang D, Moran BJ, Braccioforte MH, D’Amico AV. Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate‐risk disease. Cancer 2015; 121: 2713 – 2719.
dc.identifier.citedreferenceRaldow AC, Zhang D, Chen MH, Braccioforte MH, Moran BJ, D’Amico AV. Risk group and death from prostate cancer: Implications for active surveillance in men with favorable intermediate‐risk prostate cancer. JAMA Oncol 2015; 1: 334 – 340.
dc.identifier.citedreferenceD’Amico AV. Personalizing the management of men with intermediate‐risk prostate cancer. Eur Urol 2013; 64: 903 – 904.
dc.identifier.citedreferenceMoreira DM, Howard LE, Sourbeer KN, Amarasekara HS, Chow LC, Cockrell DC, Hanyok BT, Pratson CL, Aronson WJ, Kane CJ, Terris MK, Amling CL, Cooperberg MR, Liede A, Freedland SJ. Predicting bone scan positivity in non‐metastatic castration‐resistant prostate cancer. Prostate Cancer Prostatic Dis 2015; 18: 333 – 337.
dc.identifier.citedreferenceFreedland SJ, Sutter ME, Dorey F, Aronson WJ. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate‐specific antigen. Urology 2003; 61: 365 – 369.
dc.identifier.citedreferenceStephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, Anscher MS, Michalski JM, Sandler HM, Lin DW, Forman JD, Zelefsky MJ, Kestin LL, Roehrborn CG, Catton CN, DeWeese TL, Liauw SL, Valicenti RK, Kuban DA, Pollack A. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007; 25: 2035 – 2041.
dc.identifier.citedreferenceSchoots IG, Roobol MJ, Nieboer D, Bangma CH, Steyerberg EW, Hunink MG. Magnetic resonance imaging‐targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound‐guided biopsy: A systematic review and meta‐analysis. Eur Urol 2015; 68: 438 – 450.
dc.identifier.citedreferenceSiddiqui MM, Rais‐Bahrami S, Truong H, Stamatakis L, Vourganti S, Nix J, Hoang AN, Walton‐Diaz A, Shuch B, Weintraub M, Kruecker J, Amalou H, Turkbey B, Merino MJ, Choyke PL, Wood BJ, Pinto PA. Magnetic resonance imaging/ultrasound‐fusion biopsy significantly upgrades prostate cancer versus systematic 12‐core transrectal ultrasound biopsy. Eur Urol 2013; 64: 713 – 719.
dc.identifier.citedreferenceVolkin D, Turkbey B, Hoang AN, Rais‐Bahrami S, Yerram N, Walton‐Diaz A, Nix JW, Wood BJ, Choyke PL, Pinto PA. Multiparametric magnetic resonance imaging (MRI) and subsequent MRI/ultrasonography fusion‐guided biopsy increase the detection of anteriorly located prostate cancers. BJU Int 2014; 114: E43 – E49.
dc.identifier.citedreferencede Rooij M, Hamoen EH, Witjes JA, Barentsz JO, Rovers MM. Accuracy of magnetic resonance imaging for local staging of prostate cancer: A diagnostic meta‐analysis. Eur Urol 2016; 70 ( 2 ): 233 – 245.
dc.identifier.citedreferenceYossepowitch O, Briganti A, Eastham JA, Epstein J, Graefen M, Montironi R, Touijer K. Positive surgical margins after radical prostatectomy: A systematic review and contemporary update. Eur Urol 2014; 65: 303 – 313.
dc.identifier.citedreferenceYamoah K, Johnson MH, Choeurng V, Faisal FA, Yousefi K, Haddad Z, Ross AE, Alshalafa M, Den R, Lal P, Feldman M, Dicker AP, Klein EA, Davicioni E, Rebbeck TR, Schaeffer EM. Novel biomarker signature that may predict aggressive disease in African American men with prostate cancer. J Clin Oncol 2015; 33: 2789 – 2796.
dc.identifier.citedreferenceSundi D, Ross AE, Humphreys EB, Han M, Partin AW, Carter HB, Schaeffer EM. African American men with very low‐risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: Should active surveillance still be an option for them ? J Clin Oncol 2013; 31: 2991 – 2997.
dc.identifier.citedreferenceFaisal FA, Sundi D, Cooper JL, Humphreys EB, Partin AW, Han M, Ross AE, Schaeffer EM. Racial disparities in oncologic outcomes after radical prostatectomy: Long‐term follow‐up. Urology 2014; 84: 1434 – 1441.
dc.identifier.citedreferenceTaksler GB, Keating NL, Cutler DM. Explaining racial differences in prostate cancer mortality. Cancer 2012; 118: 4280 – 4289.
dc.identifier.citedreferenceKennedy EH, Taylor JM, Schaubel DE, Williams S. The effect of salvage therapy on survival in a longitudinal study with treatment by indication. Stat Med 2010; 29: 2569 – 2580.
dc.identifier.citedreferenceCole AI, Morgan TM, Spratt DE, Palapattu GS, He C, Tomlins SA, Weizer AZ, Feng FY, Wu A, Siddiqui J, Chinnaiyan AM, Montgomery JS, Kunju LP, Miller DC, Hollenbeck BK, Wei JT, Mehra R. Prognostic value of percent gleason grade 4 at prostate biopsy in predicting prostatectomy pathology and recurrence. J Urol 2016; 196: 405 – 411.
dc.identifier.citedreferenceVeltri RW, Isharwal S, Miller MC, Epstein JI, Partin AW. Nuclear roundness variance predicts prostate cancer progression, metastasis, and death: A prospective evaluation with up to 25 years of follow‐up after radical prostatectomy. Prostate 2010; 70: 1333 – 1339.
dc.identifier.citedreferenceSeipel AH, Delahunt B, Samaratunga H, Egevad L. Ductal adenocarcinoma of the prostate: Histogenesis, biology and clinicopathological features. Pathology 2016; 48: 398 – 405.
dc.identifier.citedreferencePatel AA, Chen MH, Renshaw AA, D’Amico AV. PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5. JAMA 2007; 298: 1533 – 1538.
dc.identifier.citedreferenceKlotz L, Vesprini D, Sethukavalan P, Jethava V, Zhang L, Jain S, Yamamoto T, Mamedov A, Loblaw A. Long‐term follow‐up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 2015; 33: 272 – 277.
dc.identifier.citedreferenceWilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, Gingrich JR, Wei JT, Gilhooly P, Grob BM, Nsouli I, Iyer P, Cartagena R, Snider G, Roehrborn C, Sharifi R, Blank W, Pandya P, Andriole GL, Culkin D, Wheeler T; Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012; 367: 203 – 213.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
pros23255.pdf
Size:
723.4KB
Format:
PDF
View/Open
Name:
pros23255_am.pdf
Size:
1.288MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.